The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The status of CAR T-cell therapy in acute and chronic leukemias
In this video, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, provides insight into a session at the EHA-EBMT European CAR T-cell Meeting 2025 focused on CAR T-cell therapy for acute and chronic leukemias. Prof. Jäger briefly discusses the status of CAR-T in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
That was a very interesting session because we’ve covered fields like acute myeloid leukemia, where we still have more questions than answers. But I thought that we got the problems presented, which is mainly how can we find an appropriate target without killing the normal myeloid cells.
For the acute lymphoblastic leukemias, we had talks on childhood ALL as well as on adult ALL...
That was a very interesting session because we’ve covered fields like acute myeloid leukemia, where we still have more questions than answers. But I thought that we got the problems presented, which is mainly how can we find an appropriate target without killing the normal myeloid cells.
For the acute lymphoblastic leukemias, we had talks on childhood ALL as well as on adult ALL. In childhood ALL I think the field is really advanced and we saw that particularly with the new trials and the real world evidence we can say that children really profit from CARs, maybe in conjunction with allogeneic transplant. For the adults, yes, we are also moving, but there are still problems related to how can we bridge patients either to CARs or to allotransplant and after CAR. So also here a bit more questions and more toxicity problems in part, but we’re moving.
In CLL, those were the first patients treated many years ago. We hear that they have still circulating CARs. So CLL is a real target. The problem there is that we are not always achieving complete responses. So it’s a very good treatment. But we have to think about ways on how to maintain the responses after CAR T-cells.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
